Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer
In the past few years, impressing improvements have been made in the treatment of advanced colorectal cancer. Following decades of modest achievements, in which it was just a matter of dose and schedule for 5-FU and leucovorin—the only treatment then available—first, the development of irinotecan an...
Main Author: | Camillo Porta |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-12-01
|
Series: | Oncology Reviews |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/72 |
Similar Items
-
Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients
by: Sato Y, et al.
Published: (2015-11-01) -
Retrospective analysis of bevacizumab and cetuximab in advanced Asian colorectal cancer patients
by: Zhang, Qian, et al.
Published: (2015) -
Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
by: P Tappenden, et al.
Published: (2007-03-01) -
Conundrum of polypharmacy in geriatrics: Less is better than more
by: V Rajesh, et al.
Published: (2021-01-01) -
Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Cheng, C.-L, et al.
Published: (2022)